2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-164010
    SUN-1334H free base 607737-00-8 98%
    SUN-1334H free base is an orally active inhibitor for histamine H1 receptor, with an IC50 of 20.3 nM and Ki of 9.7 nM. SUN-1334H free base inhibits histamine-induced contractions of isolated guinea-pig ileum with an IC50 of 0.198 μM. SUN-1334H free base inhibits histamine-induced bronchoconstriction in guinea pigs, histamine-induced skin wheals in beagle dogs, and ovalbumin-induced rhinitis in guinea pigs.
    SUN-1334H free base
  • HY-164183
    Trimethaphan bromide 21035-85-8 98%
    Trimethaphan bromide is a ganglionic blocking agent and can be used for study of hypertension.
    Trimethaphan bromide
  • HY-164534
    SIK2/3-IN-2 1648864-21-4 98%
    SIK2/3-IN-2 (compound 12, compound I-200) is a potent SIK2/3 inhibitor (SIK2 IC50 = 65 nM, SIK3 IC50 = 14 nM). SIK2/3-IN-2 is also a p21-activated protein kinase (PAK) 1 inhibitor with a Ki of 20.7 nM. SIK2/3-IN-2 can be used for hyperproliferative diseases and cancer research, such as Paclitaxel (HY-B0015)-resistant ovarian cancer.
    SIK2/3-IN-2
  • HY-164648
    Flosatidil 113593-34-3 98%
    Flosatidil (SL 85.1016) is an orally active Calcium Channel antagonist. Flosatidil has antianginal and antihypertensive properties.
    Flosatidil
  • HY-165346
    Cuspidoside 6869-51-8
    Cuspidoside is a cardiac glycoside and can be used for the research of cardiovascular disease, such as heart failure.
    Cuspidoside
  • HY-165357
    (+)-Alprenolol 23846-72-2 98%
    (+)-Alprenolol ((R)-Alprenolol; D-Alprenolol) is a 5-HT1A receptor antagonist with a Ki value of 5400 nM. (+)-Alprenolol also acts as a non-selective β-receptor (β-receptor) blocker. (+)-Alprenolol can be used in the research of cardiovascular and cerebrovascular diseases.
    (+)-Alprenolol
  • HY-165360
    JJ1 1225170-16-0
    JJ1 is a selective α-thrombin inhibitor with a Ki of 0.019 μM. JJ1 directly binds to the active site of α-thrombin to block its catalytic activity. JJ1 exhibits antithrombotic effects and prolongs activated partial thromboplastin time, prothrombin time, and tail bleeding time in mice. JJ1 can be used for the research of thrombotic diseases.
    JJ1
  • HY-165363
    AK-135 hydrochloride 75397-64-7 98%
    AK-135 hydrochloride is a Menadione (HY-B0332) derivative. AK-135 hydrochloride restores the electron flow in defective respiratory chain systems. AK-135 hydrochloride decreases LDH release, increases the amount of ATP. AK-135 hydrochloride has a protective effect against myocardial injury.
    AK-135 hydrochloride
  • HY-165397
    NA 0345 120925-60-2
    NA 0345 is a PKC inhibitor with IC50 values of 70 nM and 110 nM in the presence and absence of 12-O-tetradecanoyl-13-acetate, respectively. NA 0345 inhibits PKC and selectively suppresses the positive inotropic effect mediated by α1-adrenergic receptors.
    NA 0345
  • HY-165424
    NIR-BG2 3036456-18-2 98%
    NIR-BG2 is a near-infrared fluorescent probe targeting senescence-associated β-galactosidase (SA-β-Gal). NIR-BG2 is activated by SA-β-Gal and undergoes hydrolysis to release electrophilic quinone methide that covalently binds to surrounding proteins for in situ labeling, with a 16-fold enhancement of fluorescence signal at 709 nm . NIR-BG2 is promising for research of vivo imaging of cellular senescence.
    NIR-BG2
  • HY-165425
    KR31173 260554-07-2
    KR31173 is an AT1 antagonist with an IC50 of 3.27  nM. KR31173 can be used as a positron emission tomography (PET) tracer after being labeled with 11C isotope. KR31173 shows promising biodistribution and pharmacological properties in mice. KR31173 selectively binds to organs known to contain a high density of AT1 angiotensin receptors in CD-1 mice.
    KR31173
  • HY-165434
    Naxaprostene 87269-59-8
    Naxaprostene is a prostacyclin analogue. Naxaprostene was much more selective for IP receptors and tended towards partial agonism. Naxaprostene inhibits ADP-induced platelet aggregation. It has been shown to prevent rabbit carotid artery thrombosis.
    Naxaprostene
  • HY-165436
    Toborinone 143343-83-3 98%
    Toborinone is an inotropic agent. Toborinone increases cAMP and intracellular calcium levels through inhibiting PDE. Toborinone inhibits thrombin-induced platelet aggregation with an IC50 of 9.7 μM.
    Toborinone
  • HY-165439
    Indolidan 100643-96-7 98%
    Indolidan (LY195115) is an orally active cardiotonic agent and a selective cyclic nucleotide phosphodiesterase inhibitor. Indolidan has a Ki of 80 nM for sarcoplasmic reticulum phosphodiesterase (SR-PDE). Indolidan exhibits positive inotropic and vasodilator effects. Indolidan can be used in the research of diseases such as congestive heart failure.
    Indolidan
  • HY-165572
    AJ-3941 143110-70-7 98%
    AJ-3941 is an orally active cerebrovascular-selective Calcium Channel antagonist having anti-lipid peroxidative action. AJ-3941 can ameliorate the brain infarction and edema after permanent focal cerebral ischemia.
    AJ-3941
  • HY-165587
    BM-573 284464-83-1
    BM-573 is an orally active dual thromboxane A₂ (TXA₂) modulator with an IC50 of 1.3 nM. BM-573 possesses both thromboxane synthase (TxAS) inhibition and thromboxane receptor (TP) antagonistic effects. BM-573 can completely inhibit platelet aggregation induced by Arachidonic acid (HY-109590) or U-46619 (TXA₂ analogues). BM-573 completely blocks the generation of TXB₂ (the stable metabolite of TXA₂) in human platelets and does not inhibit cyclooxygenase (COX-1/COX-2), thus avoiding interference with other prostaglandin synthesis. BM-573 has an inhibitory effect on U-46619-induced contractions in rat gastric fundus smooth muscle (ED₅₀ = 4.2 μM), but has no effect on contractions caused by PGE₂, PGF₂α, or PGI₂. BM-573 can be used in the study of atherosclerosis, myocardial infarction, pulmonary hypertension and shock.
    BM-573
  • HY-167079
    OPC-18750 128667-63-0
    OPC-18750 is a novel positive inotropic agent and 2(lH)-quinolinone derivative. OPC-18750 displays positive inotropic and coronary vasodilating effects.
    OPC-18750
  • HY-167082
    AY 31906 124788-46-1 98%
    AY 31906 is an orally active pyrimidine sulfonamide diuretic. AY 31906 exhibits potent diuretic and natriuretic activities in rats and dogs, along with relatively potassium-sparing properties. AY 31906 exhibits superior activity to Furosemide (HY-B0135). AY-31906 also has antihypertensive effects and can be used in the research of cardiovascular diseases.
    AY 31906
  • HY-167091
    (Rac)-Beraprost 88430-50-6 98%
    (Rac)-Beraprost ((Rac)-ML 1229) is an orally active prostacyclin analog that inhibits the release of Ca2+ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis.
    (Rac)-Beraprost
  • HY-167153
    PNA5 2186644-51-7
    PNA5 is a novel, blood-brain barrier permeable glycosylated angiotensin-(1-7) peptide and MasR agonist. PNA5 inhibits IL-7, increases IL-10. PNA5 inhibits ROS generation, decreases Iba-1 expression. PNA5 exhibits sustained cognitive protective effects. PNA5 rescues blunted cerebral functional hyperemia. PNA5 can be used in the research of inflammation-related brain diseases.
    PNA5
Cat. No. Product Name / Synonyms Application Reactivity